

MAPK14 (T106M) [GST-tagged]

Kinase

Alternate Names: Cytokine-Suppressive Anti-inflammatory Drug-Binding Protein 1, CSBP1, SAPK2A, p38-Alpha

Cat. No. 66-0035-050

Lot. No. 30314

Quantity: 50 µg

Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 1 of 2

Background

Protein ubiquitylation and protein phosphorylation are the two major mechanisms that regulate the functions of proteins in eukaryotic cells. However, these different posttranslational modifications do not operate independently of one another, but are frequently interlinked to enable biological processes to be controlled in a more complex and sophisticated manner. Studying how protein phosphorylation events control the ubiquitin system and how ubiquitylation regulates protein phosphorylation has become a focal point of the study of cell regulation and human disease. MAP kinases are serine, threonine, and tyrosine specific protein kinases that regulate proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis in response to stimuli, such as mitogens, osmotic stress, heat shock and pro-inflammatory cytokines. Cloning of human Mitogen Activated Protein kinase 14 (MAPK14 or SAPK2A) was first described by Lee *et al.* (1994). An example of such interplay between phosphorylation and ubiquitylation has been highlighted in a recent study providing direct evidence for p38 α /p38 γ (MAPK14/MAPK11) in mediating oxidative stress-induced autophagy-related genes, suggesting that these MAPKs regulate both the ubiquitin-proteasome and the autophagy-lysosome systems in muscle wasting (McClung *et al.*, 2010).

Physical Characteristics

Species: human

Source: *E. coli*

Quantity: 50 µg

Concentration: 3.55 mg/ml

Formulation: 50 mM Tris/HCl pH7.5, 0.1 mM EGTA, 150 mM NaCl, 0.1% β -Mercaptoethanol, 270 mM sucrose, 0.03% Brij-35, 1 mM Benzamidine, 0.2 mM PMSF

Molecular Weight: ~67.6 kDa

Purity: >85% by InstantBlue™ SDS-PAGE


Stability/Storage: 12 months at -70°C; aliquot as required

Protein Sequence: Please see page 2

Quality Assurance

Purity:

4-12% gradient SDS-PAGE
InstantBlue™ staining
Lane 1: MW markers
Lane 2: 2.5 µg GST-MAPK14
(T106M)



Protein Identification:

Confirmed by mass spectrometry.

Activity Assay:

The specific activity of GST-MAPK14 (T106M) was determined using the method described by Hastie *et al.* (2006) with the enzyme being assayed at several concentrations. GST-MAPK14 (T106M) was incubated for 10 minutes at 30°C in kinase reaction buffer in the presence of MBP substrate (0.333 mg/ml) and [γ -32P]ATP (100 µM). Duplicate reactions were stopped by spotting the assay mixture onto Whatman P81 paper – capturing the phosphorylated substrate. The radioactivity incorporated was measured on a scintillation counter and the enzyme's mean specific activity was calculated.

GST-MAPK14 (T106M) specific activity:

107.0 Units/mg (379.7 Units/ml)

1 Unit = 1 nmole of phosphate incorporated into the substrate in 1 minute

Substrate: Myelin Basic Protein (MBP)

Continued on page 2



www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT

International: +1-617-245-0003
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

MAPK14 (T106M) [GST-tagged]

Kinase

Alternate Names: Cytokine-Suppressive Anti-inflammatory Drug-Binding Protein 1, CSBP1, SAPK2A, p38-Alpha

Cat. No. 66-0035-050

Lot. No. 30314

Quantity: 50 µg

Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 2 of 2

Background

Continued from page 1

References:

Hastie CJ, McLauchlan HJ, Cohen P (2006) Assay of protein kinases using radiolabeled ATP: a protocol. *Nat Protoc* 1, 968-71.

Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D *et al.* (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. *Nature* 372, 739-746.

Lisnock J, Tebben A, Frantz B, O'Neill EA, Croft G *et al.* (1998) Molecular basis for p38 protein kinase inhibitor specificity. *Biochemistry* 47, 16573-81.

McClung JM, Judge AR, Powers SK and Yan Z (2010) p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. *Am J Physiol Cell Physiol* 298, C542-549.

Physical Characteristics

Continued from page 1

Protein Sequence:

MSPILGYWKIKGLVQPTRLLLEYLEEKYEEH
LYERDEGDKWRNKKFELGLEFPNLPYYIDGD
VKLTQSMAIRYIADKHNMLGGCCKERAISM
LEGAVLDIRYGVSRIRIAYSKDFETLKVDL
SKLPEMLKMFEDRLCHKTYLNGDHVTHPD
FMLYDALDVVLYMDPMCLDAFPKLVCFK
KRIEAIPOIDKYLKSSKYIAWPLQGWQATFG
GGDHPPKSDLVPRGSMQERPTFYRQELNK
TIWEVPERYQNLSPVGSAYGVSVCAAFDT
KTGLRVAVKKLSRPFQSI I HAKRTYREL
RL LKHKHENVIGLLDVFTPARSLEEFND
VYLVHMLMGADLNNIVKQCQLTDDHVQFLIY
QILRGLKYIHSADI IHRDLKPSNLAVNEDCEL
KILDFGLARHTDDEMTGYVATRWYRAPEIM
LNWMHYNQTVDIWSVGC IMAELLTGRTLF
PGTDHIDQLKLILRLVGTPGAELLKKISS
ESARNYIQSLTQMPKMNFA NVF I GAN
PLAVDLLEKMLVLDSDKRITAAQALAHAY
FAQYHDPDDEPVADPYDQSFESRDLLIDEWK
SLTYDEVISFVPPPLDQEEMES

Tag (**bold text**): N-terminal GST

Protease cleavage site: Thrombin (**LVPR▼GS**)

MAPK14 (regular text): Start **bold italics** (amino acid residues 1-360).

The enzyme has the gatekeeper T106M mutation to increase resistance to SB203580 (a specific inhibitor of p38-MAPK pathway) as compared to the wildtype enzyme (Lisnock *et al.*, 1998).

Accession number: AAA57456.1



www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT

International: +1-617-245-0003
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0